Joel R. Eisner

Joel R. Eisner

Auto-generated profile, based on publicly available information

Joel R. Eisner

GeneCentric Therapeutics, Inc., Durham, North Carolina

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JEJoel R. Eisner
Joel R. Eisner
FJFlorus C de Jong
Florus C de Jong
YSYoichiro Shibata
Yoichiro Shibata
GMGregory M. Mayhew
Gregory M. Mayhew
JDJames M. Davison
James M. Davison
Tahlita ZuiverloonTahlita Zuiverloon
Tahlita Zuiverloon
Purpose: The Genomic Analysis of High-Risk Non–Muscle-Invasive Bladder Cancer (GARNER) study investigated FGFR alteration (ALT) frequency and the clinical outcome relationship with Bacillus Calmette–Guérin (BCG) treatment in high-risk non–muscle-invasive bladder cancer (HR-NMIBC). An FGFR predictive response signature (FGFR-PRS) was discovered that identifies patients with an activated FGFR pathway who could potentially benefit from FGFR-targeted therapy beyond those who are FGFR ALT (+). Experimental Design: Pretreatment tumor samples and clinical data were analyzed from 582 BCG-treated patients with HR-NMIBC. FGFR-PRS was discovered using a separate bladder cancer dataset and applied to the GARNER and other bladder cancer cohorts. FGFR-PRS was also applied to in vitro data from urothelial cancer cell lines treated with FGFR-active agents. Results: A total of 31% of pretreatment GARNER HR-NMIBC tumors were FGFR ALT (+), but this was not significantly associated with BCG response. For the subset of patients with paired pre- and post-BCG treatment samples, nearly one-third of pretreatment ALT (+) patients were ALT (−) posttreatment. FGFR-PRS identified patients with an activated FGFR pathway and identified approximately twofold additional patients compared with ALT status alone, and this increase was similar across tumor stage. A positive relationship between tumor growth inhibition and FGFR-PRS score was shown in bladder cancer in vitro models treated with FGFR-active agents. Conclusions: These data provide support for FGFR-targeted therapy use in FGFR ALT (+) HR-NMIBC and describe tumors with shared FGFR pathway–activated biology that is FGFR ALT (−) but FGFR-PRS (+). The latter suggests a broader potential patient population for FGFR-targeted therapy, which will require subsequent validation in patients treated with FGFR-targeted therapy.

30 August 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
JEJoel R. Eisner
Joel R. Eisner
KBKirk D. Beebe
Kirk D. Beebe
GMGregory M. Mayhew
Gregory M. Mayhew
YSYoichiro Shibata
Yoichiro Shibata
YGYuelong Guo
Yuelong Guo
MMMarcos E. Milla
Marcos E. Milla
Recombinant human high-dose IL2 (HD-IL2; aldesleukin) was one of the first approved immune-oncology agents based upon clinical activity in renal cell carcinoma (RCC) and metastatic melanoma but use was limited due to severe toxicity. Next-generation IL2 agents designed to improve tolerability are in development, increasing the need for future identification of genomic markers of clinical benefit and/or clinical response. In this retrospective study, we report clinical and tumor molecular profiling from patients with metastatic RCC (mRCC) treated with HD-IL2 and compare findings with patients with RCC treated with anti-PD-1 therapy. Genomic characteristics common and unique to IL2 and/or anti-PD-1 therapy response are presented, with insight into rational combination strategies for these agents.Residual pretreatment formalin-fixed paraffin embedded tumor samples from n = 36 patients with HD-IL2 mRCC underwent RNA-sequencing and corresponding clinical data were collected. A de novo 40-gene nearest centroid IL2 treatment response classifier and individual gene and/or immune marker signature differences were correlated to clinical response and placed into context with a separate dataset of n = 35 patients with anti-PD-1 mRCC.Immune signatures and genes, comprising suppressor and effector cells, were increased in patients with HD-IL2 clinical benefit. The 40-gene response classifier was also highly enriched for immune genes. While several effector immune signatures and genes were common between IL2 and anti-PD-1 treated patients, multiple inflammatory and/or immunosuppressive genes, previously reported to predict poor response to anti-PD-L1 immunotherapy, were only increased in IL2–responsive tumors.These findings suggest that common and distinct immune-related response markers for IL2 and anti-PD-1 therapy may help guide their use, either alone or in combination.Significance: Next-generation IL2 agents, designed for improved tolerability over traditional HD-IL2 (aldesleukin), are in clinical development. Retrospective molecular tumor profiling of patients treated with HD-IL2 or anti-PD-1 therapy provides insights into genomic characteristics of therapy response. This study revealed common and distinct immune-related predictive response markers for IL2 and anti-PD-1 therapy which may play a role in therapy guidance, and rational combination strategies for these agents.

26 May 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JEJoel R. Eisner
Joel R. Eisner
GMGregory M. Mayhew
Gregory M. Mayhew
JDJames M. Davison
James M. Davison
KBKirk D. Beebe
Kirk D. Beebe
YSYoichiro Shibata
Yoichiro Shibata
KMKathryn F Mileham
Kathryn F Mileham
Purpose: The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic nonsquamous (NS) non–small cell lung cancer (NSCLC) treated with pemetrexed-containing platinum doublet chemotherapy (PMX-PDC). The study tested the hypothesis that AF-PRS identifies patients with NS-NSCLC who have a higher likelihood of responding positively to PMX-PDC. The goal was to gather clinical evidence supporting AF-PRS as a potential diagnostic test. Experimental Design: Residual pretreatment FFPE tumor samples and clinical data were analyzed from 105 patients treated with first-line (1L) PMX-PDC. Ninety-five patients had sufficient RNA sequencing (RNA-seq) data quality and clinical annotation for inclusion in the analysis. Associations between AF-PRS status and associate genes and outcome measures including progression-free survival (PFS) and clinical response were evaluated. Results: Overall, 53% of patients were AF-PRS(+), which was associated with extended PFS, but not overall survival, versus AF-PRS(−) (16.6 months vs. 6.6 months; P = 0.025). In patients who were stage I to III patients at the time of treatment, PFS was further extended in AF-PRS(+) versus AF-PRS(−) (36.2 months vs. 9.3 months; P = 0.03). Complete response (CR) to therapy was noted in 14 of 95 patients. AF-PRS(+) preferentially selected a majority (79%) of CRs, which were evenly split between patients stage I to III (six of seven) and stage IV (five of seven) at the time of treatment. Conclusions: AF-PRS identified a significant population of patients with extended PFS and/or clinical response following PMX-PDC treatment. AF-PRS may be a useful diagnostic test for patients indicated for systemic chemotherapy, especially when determining the optimal PDC regimen for locally advanced disease.

25 November 2025
Verified
Other
Open access
JEJoel R. Eisner
Joel R. Eisner
GMGregory M. Mayhew
Gregory M. Mayhew
JDJames M. Davison
James M. Davison
KBKirk D. Beebe
Kirk D. Beebe
YSYoichiro Shibata
Yoichiro Shibata
KMKathryn F Mileham
Kathryn F Mileham
Expression of Genes Associated with Antifolate (Pemetrexed) Activity by LUAD Subtype.


4 April 2023
Verified
Other
Open access
JEJoel R. Eisner
Joel R. Eisner
KBKirk D. Beebe
Kirk D. Beebe
GMGregory M. Mayhew
Gregory M. Mayhew
YSYoichiro Shibata
Yoichiro Shibata
YGYuelong Guo
Yuelong Guo
MMMarcos E. Milla
Marcos E. Milla
40 gene IL-2 response classifier and related immune cell types